The currently available antiplatelet drugs target key steps of platelet activation including thromboxane A 2 synthesis, ADP-mediated signaling, and glycoprotein IIb/IIIa-mediated platelet aggregation.

The research team discovered that platelets release a substance called thromboxane A2 (TXA2), which attaches to receptors on T cells and activates a protein called ARHGEF1. This interaction ...

Activated platelets catalyze thromboxane A 2 synthesis in bursts from endogenous platelet arachidonic acid, which is present at a low concentration. Important considerations when investigating ...

One of these evasion methods involves the production of thromboxane A2 (TXA2) by blood platelets, which suppresses the ...

Aspirin 25mg (immediate-release), dipyridamole 200mg (extended-release); caps. Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo.

Researchers found that aspirin decreases thromboxane A2 (TXA2) production, thus preventing T cell suppression and reducing the frequency of metastases in mice models. This discovery suggests a ...

an activity that might be relevant to situations in which this thromboxane metabolite is formed in high concentrations, such as at sites of platelet aggregation. Vasodilatation leading to erythema ...